Overview

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
National Cancer Institute (NCI)
Treatments:
Trastuzumab